Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Murine and Humanized Mouse Models in Autoimmune Disease Research and Therapeutics Development
Nikhat, Sameena , Bose, Suman , Khosravi-Maharlooei, Mohsen , Khosravi-Maharlooei, Mohsen

Biology | July 10, 2026 | Volume: 15 | Issue: 14 | Pages: 1125

10.3390/biology15141125 | PMID 42510675 Get It

Autoimmune diseases arise from a breakdown of immune tolerance and complex interplay of genetic susceptibility, environmental triggers, tissue-specific immune responses, microbiota, and regulatory pathways. Mouse models remain essential for dissecting these mechanisms, but no single model fully reproduces the heterogeneity, chronicity, and immune complexity of autoimmune disease in humans. This review summarizes classical murine and humanized mouse models used to study inflammatory bowel disease (IBD), multiple sclerosis (MS), type-1 diabetes (T1D), and rheumatoid arthritis (RA). We also highlight disease-specific scoring systems, including clinical indices, histopathology, imaging, cytokine profiling, autoantibody assessment, and human immune-cell readouts, as essential tools for standardized interpretation. Conventional murine models provide experimental control and mechanistic clarity, whereas humanized models improve assessment of human immune responses, patient-specific biology, and therapeutic translation. However, humanized systems remain limited by incomplete immune reconstitution, graft-versus-host disease, donor variability, cost, and incomplete tissue architecture. By providing a comparative framework spanning both conventional and humanized models, this review aims to guide informed model selection tailored to specific research questions in autoimmune disease biology and translational therapeutic development.
Establishing a Specialty Bipolar Clinic: The National Network of Depression Centers Consensus Recommendations
Schneck, Christopher D. , Bond, David J., Burdick, Katherine E. , Frye, Mark A. , Huber, Rebekah S., Mahon, Pamela, McInnis, Melvin G., Nurnberger, John, Öngür, Döst , Ostacher, Michael J., Parikh, Sagar V. , Raj, Kristin S. , Schweizer, Barbara , Soares, Jair C., Sullivan, Aimee E. , Suppes, Trisha , Zandi, Peter P. , Ostacher, Michael J. , Bond, David J. , Burdick, K E , Frye, Mark , Sperry, Sarah , Zandi, Peter P , DePaulo, J Raymond , Bond, David J , Ostacher, Michael J , Almeida, Jorge , Goes, Fernando , Huber, Rebekah S. , Machado‐Vieira, Rodrigo , Mahon, Pamela B. , McInnis, Melvin G. , Nurnberger, John I , Respino, Matteo , Soares, Jair C. , Sperry, Sarah H. , Veldić, Marin

Bipolar Disorders | July 10, 2026 | Volume: 28 | Issue: 5 | Pages: No page available

10.1111/bdi.70154 | PMID 42429592 Get It

ABSTRACT Objective To provide expert recommendations for the development of a specialty bipolar clinic that promotes best clinical practices for the delivery of safe and effective care. Methods Members of the National Network of Depression Centers (NNDC) Bipolar Clinics Work Group met in a series of 1‐h monthly video calls over 18 months to discuss all aspects of their respective institution's bipolar clinics, including services provided, administrative processes, staffing models, characteristics of patients treated, patient volumes, finances, and research. The group also invited psychiatrists from outside of the NNDC who ran large bipolar clinics to contribute their thoughts and experiences on the subject. In addition, the NNDC sent a 20‐question survey to all 27 sites asking clinic directors specific questions about their bipolar clinics, if applicable. Further meetings and discussions incorporating results from the survey took place to produce a comprehensive set of recommendations. Results Twenty‐one of 27 NNDC sites (81%) responded to the survey. Twelve of 21 (57%) sites had a specific bipolar clinic, and another 4 (19%) were looking to start one. Clinics were based in university settings. The meetings, clinic survey, and discussions resulted in 10 recommendations describing services and operations for bipolar specialty clinics. Conclusions Given the complexity of bipolar disorder, specialty clinics are important to enhance care. Clinics with a wide array of services that include consultation, medication management, bipolar‐specific psychotherapies, and patient/family psychoeducation provide the most comprehensive care. Challenges to these clinics include maintaining ongoing patient access as well as ensuring long‐term financial stability.
Photo Quiz: An unusual finding in an ileal conduit urine cytology specimen
Rattin, Jacob , Jerrett, Isago, Pritt, Bobbi S. , Shah, A, Pritt, Bobbi S , Shah, Akeesha A.

Journal of Clinical Microbiology | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1128/jcm.00327-26 | PMID 42429556 Get It

Association of Charlson Comorbidity Index with Clinical Characteristics and Outcomes in Heart Failure
Farooqui, Naba , Benson, Lina, Thorvaldsen, Tonje , Shahim, Bahira , Redfield, Margaret M, Dunlay, S M, Savarese, Gianluigi , Lund, Lars H. , Dunlay, Shannon M. , Benson, Lina , Redfield, Margaret M.

ESC Heart Failure | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eschf/xvag165 | PMID 42471240 Get It

Abstract Background The Charlson comorbidity index (CCI) is a validated weighted measure of comorbidity burden, but has an unclear role in heart failure (HF). Objectives To characterize age-adjusted CCI (ACCI) in HF, its association with the use of guideline-directed medical therapy (GDMT) and with outcomes. Methods In the Swedish HF registry, patients were divided into 3 groups based on ACCI scores (low 1-3, intermediate 4-6, and high ≥7). We studied its association with clinical characteristics and GDMT use. Multivariable multinominal and Cox regressions were used to analyze ACCI and its association with ejection fraction (EF) category (reduced [HFrEF], mildly reduced [HFmrEF], preserved [HFpEF]), and with outcomes up to 3 years. Results Among 117,419 patients (age 75 [66-82], 36% women, 53% HFrEF, 24% HFmrEF, 23% HFpEF, median ACCI was 5, 6 and 6 respectively. ACCI ≥7 was present in 31% with HFrEF, 35% with HFmrEF and 42% with HFpEF. A higher ACCI score was associated with higher EF category, NYHA class, serum NT-proBNP, diuretic use, and lower quality of life and GDMT use (p<0.05 for all). The risk of composite CV mortality/first HF hospitalization was higher with intermediate (adjusted HR 1.34, 95% CI 1.29-1.39) and high vs low ACCI (1.76, 1.69-1.83). High ACCI category (vs low) was significantly associated with non-CV (adjusted HR 6.36, 95% CI 5.75-7.04), but also, CV mortality (4.35, 3.99-4.74), and total hospitalizations (adjusted IRR 2.16, 2.11-2.22) but also HF hospitalizations 1.23 (1.17-1.28) Conclusion The ACCI discriminates well in HF, with higher ACCI being associated with greater severity of HF, lesser GDMT use and worse quality of life. Higher ACCI was more strongly associated with death than hospitalization. Higher ACCI was more strongly associated with non-CV outcomes but also with CV and HF outcomes.
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression
Hayek, Mohammad Al , Estevinho, María Manuela , Kayal, Maia , Hayek, Osamah Al, Armuzzi, Alessandro , Burisch, Johan, Najah, Qasi , Wexner, Steven D, Loftus, Edward V. , Burisch, Johan , Jairath, V , Loftus, Edward V , Peyrin-Biroulet, Laurent , Danese, Silvio , Elhadi, Muhammed , Magro, F , Kayal, Maia , Jairath, Vipul , Wexner, Steven D , Peyrin‐Biroulet, Laurent , Danese, Silvio , Elhadi, Muhammed , Magro, Fernando

Journal of Crohn's and Colitis | July 10, 2026 | Volume: 20 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjag111 | PMID 42570330 Get It

Abstract Background The expanding use of biologic and small-molecule therapies for ulcerative colitis (UC) has raised concerns regarding perioperative safety. We conducted a network meta-analysis to compare short-term postoperative complications associated with preoperative exposure to these agents in patients undergoing colorectal surgery. Methods We systematically searched PubMed, Web of Science, and the Cochrane Library through September 15, 2025, for cohort studies of adults with UC who were exposed to biologic or small-molecule therapy within 12 weeks prior to surgery. Interventions included biologic therapy, small-molecule therapy, and no biologic or small-molecule therapy (control). The primary outcome was overall postoperative complications at 30 and 90 days. Venous thromboembolism (VTE) was assessed as a key secondary outcome. Random-effects network meta-analysis was performed using risk ratios (RRs) with 95% confidence intervals (CIs). Results Sixteen retrospective cohort studies involving 3235 patients were included. At 30 days, ustekinumab and tofacitinib were associated with lower overall postoperative complication rates than control (RR: 0.29; 95% CI: 0.09-0.96; and RR: 0.66; 95% CI: 0.46-0.96, respectively). Anti-tumor necrosis factor (TNF) therapy was associated with higher complication rates compared with vedolizumab, ustekinumab, and tofacitinib at 30 days (RR: 1.27; 95% CI: 1.00-1.63; RR: 3.67; 95% CI: 1.12-12.03; and RR: 1.61; 95% CI: 1.14-2.27, respectively). At 90 days, anti-TNF therapy was associated with higher complication rates than control (RR 1.20, 95% CI 1.03-1.40), although the 90-day analysis was based on limited data. VTE rates were similar across treatments at both time points. Conclusion Preoperative ustekinumab and tofacitinib were associated with fewer 30-day postoperative complications than control or anti-TNF therapy, while vedolizumab was associated with fewer complications than anti-TNF therapy. At 90 days, anti-TNF therapy was associated with higher complication rates compared with control. These findings, particularly at 90 days based on limited data, should be interpreted with caution and require confirmation in well-designed prospective studies with rigorous adjustment for confounding factors.
Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features
Gandhi, Shreya, Ocaña-Tienda, Beatriz , Bettencourt, Manuel M., Singh, O, Devaraja, Kaviya , Irish, Emily R., Molina-García, David , Karimi, Shirin, Sosa, Julio , McIntyre, Ian, Gao, Andrew , Ramos-González, Ana, Asenjo, Beatriz , Flores-Rial, María Pino, Aldape, Kenneth , Santos, Carlos, Velásquez, Carlos, Mansouri, Alireza, Zadeh, Gelareh, Singh, Olivia S, Pérez-Beteta, Julián , Asenjo, Beatriz , Sánchez-Gómez, Pilar , Aldape, Kenneth D, Santos, Carlos , Mansouri, Alireza , Zadeh, Gelareh , Mansouri, Sheila , Mamatjan, Yasin , Hernández‐Laín, Aurelio , Drummond, Katharine Jann , Parney, Ian F. , Velásquez, Carlos , Mansouri, Alireza , Pérez‐García, Víctor M. , Mansouri, Sheila

Neuro-Oncology Advances | July 10, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag182 | PMID 42553785 Get It

Abstract Background Glioblastoma (GB) exhibits marked tumor microenvironmental heterogeneity, contributing to both therapy resistance and poor survival outcomes. Intercellular adhesion molecule 1 (ICAM1) is an inflammation-associated adhesion molecule implicated in immune-stromal interactions, but its clinical and biological significance in GB remains incompletely defined. Methods We performed ICAM1 immunohistochemistry, bulk RNA sequencing, DNA methylation analysis, single-nucleus RNA sequencing, and preoperative MRI-derived morphologic feature analysis across multi-institutional cohorts of treatment-naïve IDH-wildtype GB. Results High ICAM1 expression at both transcript and protein levels is associated with shorter overall survival, particularly within the mesenchymal transcriptional subtype. ICAM1 expression is inversely associated with promoter methylation. Single-nucleus RNA-sequencing analysis shows that ICAM1-high tumors are enriched for mesenchymal, hypoxia, stress-associated, and immunosuppressive myeloid programs, suggesting that ICAM1 reflects a multicompartment inflammatory tumor ecosystem. ICAM1 expression, tumor surface irregularity, and patient age are independently prognostic and minimally correlated, capturing complementary clinical, imaging, and molecular features of GB biology. When combined, our Clinical-Imaging-Molecular (CIM) framework refines outcome prediction across independent GB cohorts using routinely available clinical data, conventional imaging, and standard immunohistochemistry. Conclusions ICAM1 characterizes an immune-remodeled, stress-adapted GB ecosystem associated with poor clinical outcomes. Integrating patient age, surface irregularity, and ICAM1 expression yields a scalable and clinically accessible prognostic framework for GB, supporting tailored outcome prediction, particularly in low- and middle-resource settings without routine access to advanced molecular profiling.
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
Sharara, Sima L. , Diaz, Lorena, Asempa, Tomefa E, Martinez, Jose R W, Canales, Nicolas, Bergman, Yehudit , Murphy, Shannon G. , Karaba, Sara M. , Clark, Andrew E. , Zurawski, Daniel V, Cosgrove, Sara E, Simner, Patricia J, Munita, José M. , Tamma, Pranita D. , Tamma, Pranita D , Clark, Andrew E. , Karaba, Sara M , Bergman, Yehudit , Munita, Jose M , Sharara, Sima L. , Díaz, Lorena , Asempa, Tomefa E. , Canales, Nicolás, Murphy, Shannon G. , Zurawski, Daniel V. , Cosgrove, Sara E. , Simner, Patricia J.

Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag436 | PMID 42442753 Get It

Abstract We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
Bacteriophage Therapy of Mycobacterium abscessus Mastoiditis
Becken, Bradford , Lauer, Michael J , Russell, Daniel A, Garlena, Rebecca A , Cristinziano, Madison, Abad, Lawrence, Dedrick, Rebekah M, Jacobs-Sera, Deborah, Driscoll, Colin, Zwiener, Jennifer, Hatfull, Graham F , Becken, Bradford , Lauer, Michael J , Russell, Daniel A. , Garlena, Rebecca A. , Cristinziano, Madison, Abad, Lawrence , Dedrick, Rebekah M. , Jacobs‐Sera, Deborah , Driscoll, Colin L. W., Zwiener, Jennifer, Hatfull, Graham F.

Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag439 | PMID 42455053 Get It

Abstract We describe a case of a child with macrolide-resistant Mycobacterium abscessus who initially had clinical improvement on a dual β-lactam regimen but continued to have positive cultures. Suitable phages active against the bacterial strain were identified, administered both systemically and directly to the ear, and were associated with microbiological remission.
Angiotensin II Type 1 Receptor Expression and Anti-AT1R Antibodies in Heart Transplantation: A Systematic Review of Distinct but Related Non-HLA Immune Pathways
Gopalan, Radha, Reyad, Mohamed , Mahar, Jamal, Kalya, Anantharam, Reinsmoen, Nancy, Arabia, Francisco, Mohamed, Mohamed Reyad , Mahar, Jamal Hussain , Sunkara, Anusha , Hafez, Abdelrahman , Reinsmoen, Nancy L.

Journal of Clinical Medicine | July 10, 2026 | Volume: 15 | Issue: 14 | Pages: 5419

10.3390/jcm15145419 | PMID 42513331 Get It

Background: Heart transplantation (HT) remains the definitive therapy for end-stage heart failure, yet rejection and cardiac allograft vasculopathy (CAV) continue to limit long-term outcomes. Beyond donor-specific HLA antibodies, non-HLA antibodies, particularly anti-angiotensin II type 1 receptor antibodies (AT1R-Abs), have been implicated in allograft injury, but published findings are heterogeneous. Aim: The aim of this study is to systematically evaluate the evidence linking AT1R gene expression and anti-AT1R antibodies with key post-heart transplant outcomes. Methods: We conducted a systematic review in accordance with PRISMA guidelines. Scopus, PubMed, Web of Science, and the Cochrane Library were searched (December 2025) for cohort and case–control studies evaluating AT1R gene expression and/or AT1R-Ab status in HT recipients and their association with post-transplant outcomes. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the NIH Quality Assessment Tool. Results: Twelve studies encompassing 951 recipients met the inclusion criteria. Five studies evaluated AT1R mRNA expression, reporting variable patterns: several observed reduced AT1R/AT2R transcription after transplantation without clear clinical correlation, whereas others associated higher donor or recipient AT1R expression with transplant coronary artery disease and recurrent rejection. AT1R-Ab prevalence varied widely and appeared to increase after mechanical circulatory support, with substantial seroconversion reported during LVAD support in initially antibody-negative patients. Associations between AT1R-Ab and acute cellular rejection and antibody-mediated rejection were inconsistent across studies, and survival findings were inconclusive; however, some reports linked elevated AT1R-Abs to poorer long-term freedom from adverse events. Evidence regarding CAV was mixed, with signals of increased vasculopathy risk in some cohorts but not others. Conclusions: Current evidence suggests a potential role for AT1R expression and AT1R-Abs in cardiac allograft dysfunction, including rejection phenotypes and vasculopathy. Larger prospective studies with harmonized testing strategies are needed to define clinically meaningful AT1R-Ab cutoffs and clarify their utility in risk stratification and targeted therapeutic trials.
Extracorporeal Magnetotransduction Therapy (EMTT) for Midfoot Osteoarthritis: A Prospective Pilot Study of Pain and Functional Outcomes
Charles, Rohan, Vlasak, Alexander , Bondi, Elizabeth , Vlasak, Alexander

Journal of the American Podiatric Medical Association | July 10, 2026 | Volume: 116 | Issue: 4 | Pages: 51

10.3390/japma116040051 | PMID 42496340 Get It

Extracorporeal magnetotransduction therapy (EMTT) is a high-energy electromagnetic modality that delivers field strengths of 80–150 mT, effective transduction power > 60 kT/s, and dual-frequency architecture with pulse repetition near 8 Hz and oscillations of 100–300 kHz. This prospective pilot study evaluated pain and functional outcomes in patients with symptomatic midfoot osteoarthritis (OA). Eight patients (13 feet; five bilateral and three unilateral cases) with radiographic Kellgren–Lawrence (KL) grade 3 or 4 midfoot OA received eight EMTT sessions over four weeks. Outcomes were measured at baseline, after the eighth treatment at four weeks, and at 3-month and 6-month follow-up using the 0–10 Visual Analog Scale (VAS) and Foot and Ankle Ability Measure—Activities of Daily Living (FAAM-ADL). VAS demonstrated a significant overall effect of time (F(3,36) = 3.93, p = 0.016), with mean scores decreasing from 4.15 ± 1.63 at baseline to 2.62 ± 1.98 at 3 months and 3.00 ± 2.08 at 6 months. Bonferroni-adjusted baseline-to-follow-up contrasts approached significance at 3 months (p = 0.067) and were not significant at 6 months (p = 0.150). FAAM-ADL improved significantly over time (F(3,30) = 13.76, p < 0.001), increasing from 61.7% ± 9.9% at baseline to 81.8% ± 11.1% at 6 months. No treatment-related adverse events were observed; one participant proceeded to surgery by 6 months and was classified as a treatment failure. These preliminary findings suggest that EMTT is safe and may provide clinically meaningful functional improvement in selected patients with midfoot OA; larger sham-controlled trials are needed.